Jazz Pharmaceuticals
JAZZ Nasdaq· Pharmaceuticals
Last close · Oct 27, 2026
$206.78
KIRA · Stoqly’s AI analyst, in plain words
- Jazz Pharmaceuticals had $4.3B of revenue in fiscal 2025, up 4.9% on the year before. Over five years, revenue changed +12.5% a year on average.
- Its operating margin was −10.1%, down 27.7 pts: of every 100 in sales, about −10 is left after running the business.
- Jazz Pharmaceuticals lost $356M in fiscal 2025.
- Free cash flow was $1.3B in fiscal 2025, 30.4% of revenue.
- Jazz Pharmaceuticals returned $125M to shareholders in fiscal 2025, 10% of free cash flow. The diluted share count fell 7.6%.
- Jazz Pharmaceuticals owes $4.0B more than it holds in cash.
Market cap
$14.4B
P/E
14.1x
Revenue
$4.3B
Net income
−$356M
Free cash flow
$1.3B
Operating margin
−10.1%
Jazz Pharmaceuticals in 30 seconds · fiscal 2025
Are sales growing?
+4.9%
Only a little. Sales grew 4.9% last year.
Does it make a profit?
−8.4%
No. It lost money last year.
Does profit turn into cash?
30.4%
Yes. 30.4% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
14.1x
One share costs 14.1 times its yearly profit per share. Typical for its sector: 28.4x.
What Jazz Pharmaceuticals does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Jazz Pharmaceuticals plc
- CIK
- 0001232524
Jazz Pharmaceuticals · JAZZ
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.1B | $3.7B | $3.8B | $4.1B | $4.3B |
| Revenue growth | 30.9% | 18.3% | 4.8% | 6.1% | 4.9% |
| Operating margin | 5.5% | −1.8% | 15.1% | 17.6% | −10.1% |
| Net income | −$330M | −$224M | $415M | $560M | −$356M |
| Net margin | −10.7% | −6.1% | 10.8% | 13.8% | −8.4% |
| Diluted EPS | −$5.52 | −$3.58 | $6.10 | $8.65 | −$5.84 |
| Cash | |||||
| Cash from operations | $779M | $1.3B | $1.1B | $1.4B | $1.4B |
| Capital expenditure | $27.6M | $29.0M | $24.0M | $38.1M | $58.8M |
| Free cash flow | $751M | $1.2B | $1.1B | $1.4B | $1.3B |
| FCF margin | 24.3% | 34.0% | 27.9% | 33.4% | 30.4% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.1M | $270M | $311M | $125M |
| Share count change | 5.6% | 4.8% | 15.2% | −8.4% | −7.6% |
| Debt and strength | |||||
| Cash and short-term investments | $591M | $882M | $1.5B | $2.4B | $1.4B |
| Debt incl. finance leases | $6.1B | $5.7B | $5.7B | $6.1B | $5.4B |
| Shareholders' equity | $4.0B | $3.1B | $3.7B | $4.1B | $4.3B |
| Current ratio | 3.2x | 2.8x | 2.2x | 4.5x | 1.9x |
| Interest coverage | 1.9x | −2.0x | 17.6x | 2.3x | −1.7x |
| Returns and quality | |||||
| Return on capital | 1.9% | −0.6% | 7.3% | 9.1% | −4.2% |
| Return on equity | −8.7% | −6.4% | 12.2% | 14.3% | −8.5% |
| Piotroski F-score | 3 | 4 | 5 | 7 | 4 |
| Altman Z'' | 1.8 | 1.6 | 2.2 | 3.2 | 1.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$69.8M
11 insiders
Of sales under plans
48%
$33.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Jazz Pharmaceuticals · JAZZ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals JAZZ | $14.4B | 4.9% | −10.1% | 30.4% | −4.2% | 14.1x | 4 |
| Elanco ELAN | $11.5B | 6.2% | — | 6.0% | −0.1% | — | 6 |
| Amneal Pharmaceuticals AMRX | $7.0B | 8.1% | 13.1% | 8.9% | 16.1% | 43.8x | 7 |
| Zoetis ZTS | $32.7B | 2.3% | — | 24.1% | 29.3% | 12.9x | 8 |
| Bausch Health Companies BHC | $2.4B | 6.7% | 17.7% | 9.8% | 4.5% | — | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $206.78 a share, the company is worth $14.4B: 14.1 times its earnings of the last four quarters.
Jazz Pharmaceuticals grew sales faster than 1 of its 4 similar companies. Its P/E is higher than 1 of 2.
Source: SEC EDGAR XBRL filings (CIK 0001232524). Data updated October 16, 2026. For information only — not investment advice. Check the original filings before relying on any figure.